MedPath

Influence of Beer on Gut Microbiota and Biochemical Outcomes: Alcohol Impact.

Not Applicable
Completed
Conditions
Healthy Volunteers
Interventions
Dietary Supplement: Beer with 5.20 % alcohol
Dietary Supplement: Non-alcoholic beer with 0.45 % alcohol
Dietary Supplement: Non-alcoholic beer with 0.00 % alcohol
Registration Number
NCT03513432
Lead Sponsor
Universidade do Porto
Brief Summary

Our aim is to assess the effects of moderate consumption of beer and non-alcoholic beer on gut microbiota and biochemical biomarkers in healthy adults.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
30
Inclusion Criteria
  • Adult men (18-65 years);
  • Healthy volunteers free of chronic diseases with relevant effect on gastrointestinal system;
  • Without a diagnosis of any digestive disease including functional bowel disorders such as IBS;
  • Moderate alcohol consumers;
  • Willing and able to provide written informed consent.
Exclusion Criteria
  • Documented cardiovascular disease (ischaemic heart disease - angina or recent or old myocardial infarction or previous or cerebral vascular accident, peripheral vascular disease);
  • With diabetes or other relevant metabolic diseases;
  • With any known infectious diseases, namely infections with HIV, Hepatitis B or C virus;
  • Intake of antibiotics in the last 4 weeks and laxatives in the last 2 weeks;
  • Subjects with history of drug, alcohol or other substances abuse.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Beer with 5.20 % alcoholBeer with 5.20 % alcohol330 ml beer (5.20 % alcohol)/day
Non-alcoholic beer with 0.45 % alcoholNon-alcoholic beer with 0.45 % alcohol330 ml non-alcoholic beer (0.45 % alcohol)/day
Non-alcoholic beer with 0.00 % alcoholNon-alcoholic beer with 0.00 % alcohol330 ml non-alcoholic beer (0.00 % alcohol)/day
Primary Outcome Measures
NameTimeMethod
Changes in intestinal microbiota from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Secondary Outcome Measures
NameTimeMethod
Changes in fasting serum triglycerides from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Changes in fasting serum cHDL from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Changes in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Changes in fasting serum total cholesterol from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Changes in fasting serum cLDL from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Changes in fasting serum LPS levels from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)
Changes in body mass index from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)

Weight and height will be combined to report BMI in kg/m\^2.

Changes in total body fat mass from baselineat visit 1 (after 1-week run-in period) and at visit 2 (after 4-week intake period)

Trial Locations

Locations (1)

Faculdade de Ciências Médicas da Universidade NOVA de Lisboa

🇵🇹

Lisboa, Portugal

© Copyright 2025. All Rights Reserved by MedPath